Press release
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
Studies have shown that using Castle’s DecisionDx®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer,
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nStudies have shown that using Castle’s DecisionDx®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes1-5\n\n\nCastle’s management team will also ring the New York Stock Exchange closing bell on Sept. 28 as a member of the Texas Capital Texas Equity Index exchange traded fund (ETF)\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company will ring the Nasdaq closing bell on Wednesday, Sept. 27, 2023, to raise awareness of melanoma in honor of patients impacted by the disease.\n\n\n“Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member. “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care. At the end of the day, we are all working together to make an impact in people’s lives and perhaps provide something even more powerful than that … hope for the future.”\n\n\nMelanoma will claim nearly 20 American lives each day this year, making it the most aggressive form of skin cancer.6 Castle’s DecisionDx-Melanoma test is designed to provide personalized information about a patient’s risk of melanoma recurrence, metastasis and sentinel lymph node positivity based on the biology of their tumor. This information can inform important decisions regarding a patient’s treatment and follow-up care that have been shown to improve health outcomes.1-5\n\n\nAlong with Castle’s leadership team at the Nasdaq closing bell ceremony will be the following:\n\n\n\nDarrell Rigel, M.D., M.S., dermatologist, leading melanoma expert and clinical professor of dermatology at the Mount Sinai Icahn School of Medicine in New York. Rigel is also the co-creator of the ABCDEs of early melanoma detection, a standard in today’s dermatologic practice designed to help the public and clinicians identify features of suspicious skin lesions.\n\n\n\nEd Dobbles, D.B.A., IMPACT Melanoma board member. IMPACT Melanoma is the nation’s lead...